The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 23 March 2004, www.theannals.com, DOI 10.1345/aph.1D261.
 The Annals of Pharmacotherapy: Vol. 38, No. 5, pp. 845-852. DOI 10.1345/aph.1D261
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chong, P. H
Right arrow Articles by Cheng, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chong, P. H
Right arrow Articles by Cheng, J. W.

CARDIOLOGY

Early Experiences and Clinical Implications of Restenosis and Drug-Eluting Stents: Part 2

Pang H Chong, PharmD

Clinical Assistant Professor, University of Illinois at Chicago, Chicago, IL; Clinical Adjunct Instructor, Midwestern University, Downers Grove, IL; Clinical Coordinator, Medical Cardiology & Lipid Clinic, John H Stroger, Jr Hospital, Chicago

Judy WM Cheng, PharmD BCPS

Associate Professor of Pharmacy Practice, Long Island University, New York, NY; Clinical Pharmacy Specialist of Cardiology, Mount Sinai Medical Center, New York

Reprints: Pang H Chong PharmD, Department of Pharmacy (#LL170), John H Stroger, Jr Hospital, 1901 W. Harrison St., Chicago, IL 60612-3914, fax 312/864-9287, cpang{at}tigger.cc.uic.edu

OBJECTIVE: To review early clinical experience and future implications of drug-eluting stents (DES) in percutaneous coronary interventions.

DATA SOURCES: Using the search terms sirolimus, paclitaxel, and drug-eluting stents, a literature review was conducted to identify peer-reviewed articles and abstracts in MEDLINE (1966–June 2003). Recent meeting abstracts were also accessed through the American Heart Association and the American College of Cardiology Web sites. Citations from available articles were reviewed for additional references.

STUDY SELECTION AND DATA EXTRACTION: Published reviews and studies showing the effects of in-stent restenosis and drug-coated and -eluting stents were evaluated and reviewed.

DATA SYNTHESIS: Current antiplatelet and antithrombotic therapy have proven successful in preventing acute in-stent thrombosis, but not in-stent restenosis. Recently, stents eluted with certain antimitotic agents have demonstrated positive findings in reducing restenosis (eg, sirolimus, paclitaxel-eluting stents) compared with bare-metal stents. However, data regarding long-term benefits and adverse effects are only beginning to accumulate.

CONCLUSIONS: While the current clinical efficacy and safety of DES appear promising, further investigations are required to examine long-term efficacy, safety, and cost-effectiveness. Subanalysis of the current data may help to determine the specific patient population that may benefit maximally from DES.

Key Words: drug-eluting stent, percutaneous coronary intervention, restenosis

Published Online, March 23, 2004. www.theannals.com, DOI 10.1345/aph.1D261


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
J Butany and M J Collins
Analysis of prosthetic cardiac devices: a guide for the practising pathologist
J. Clin. Pathol., February 1, 2005; 58(2): 113 - 124.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.